Automated Insulin Delivery Systems MARKET SWOT ANALYSIS AND SURGE FROM 2020-2027

1
Automated Insulin Delivery Systems Market To
Reach USD 7.81 Billion By 2027
www.reportsanddata.com
sales_at_reportsanddata.com
2
Market Summary
Rise in the global burden of diabetes, increasing
geriatric population, growing rate of obesity,
favorable reimbursement policies, increasing
strategic initiatives such as product launches or
collaborations, and favorable investment
scenarios are among the key factors contributing
to a high CAGR of the Automated Insulin Delivery
Systems market during the forecast
period. Market Size USD 4.91 Billion in 2019,
Market Growth - CAGR of 6.0, Market Trends
Technological advancements and rising demand for
user friendly point of care insulin delivery
system
3
Our Approach
Market Summary

• According to the current analysis of Reports and
  Data, the global Automated Insulin Delivery
  Systems Market was valued at USD 4.91 billion in
  2019 and is expected to reach USD 7.81 billion by
  the year 2027 at a CAGR of 6.0. The Automated
  Insulin Delivery Systems (AID) market is majorly
  driven due to the increasing prevalence of
  diabetes across the globe. Diabetes is a chronic
  metabolic disease characterized by increased
  blood glucose levels or blood sugar, which is
  likely to lead to heart disorders, damage to
  blood vessels, eyes, kidneys, and nerves. In
  2019, nearly 463 million adults from 20 to 79
  years old had diabetes and is estimated to rise
  to about 700 million by 2045 globally, according
  to the International Diabetes Federation.
• The continuous growth in the target population
  has promoted a rise in technological advances in
  the field emerging tremendous future opportunity
  for Automated Insulin Delivery Systems. For
  instance, one of the leading players in the
  industry Bigfoot Biomedical is engaged in
  developing its advanced AID system Autonomy with
  the use of a screenless pump, a smartphone app,
  and the FreeStyle Libre CGM which is estimated
  to be launched by 2023. Increasing technological
  developments, favorable reimbursement policies,
  and increasing awareness programs are estimated
  to support the market growth. Furthermore, rising
  diabetic population worldwide has attracted
  research investments from private and public
  organizations, towards diabetes management. For
  instance, the NIH has invested in collaboration
  with four institution to support development of
  closed-loop insulin delivery technology or
  Automated Insulin Delivery Systems for pregnant
  women with type 1 diabetes in 2019.
• To Get Sample Copy of Report visit
  https//www.reportsanddata.com/sample-enquiry-form
  /3453

4
Our Approach
Market Summary

• Key participants include Novo Nordisk A/S,
  Sanofi, Eli Lilly and Company, Biocon, Ypsomed,
  Wockhardt, Digital Medics, Abbott, Companion
  Medical, F. Hoffmann-La Roche, Ltd., BD, Animas
  LLC, Medtronic., Tandem Diabetes Care, Inc,
  Diabetes Care, BIGFOOT BIOMEDICAL, INC, DreaMed
  Diabetes, Ltd and WTWH Media LLC
• Segments covered in the report
• Applications Outlook (Revenue in Million USD
  20172027)
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus
• End Use outlook (Revenue in Million USD
  20172027)
• Homecare
• Hospitals
• Clinics
• Others
• To get a Discount on the Automated Insulin
  Delivery Systems Market Report, Click _at_
  https//www.reportsanddata.com/discount-enquiry-fo
  rm/3453

5
Our Approach
Market Summary

• Product Type Outlook (Revenue in Million USD
  20172027)
• Devices
• A) Pens
• a)Reusable Insulin Pens
• b)Disposable Insulin Pens
• B) Insulin Pumps
• a)External/ Tethered Pumps
• b)Patch Pumps
• c)Implanted Insulin pump (IIP)
• d)Closed loop insulin pump (artificial
  pancreas)
• C) Pen Needles
• a)Standard Pen Needles
• b)Safety Pen Needles
• D) Insulin Syringes
• E) CGM
• Software Mobile App
• Others

6
Our Approach
Market Summary

• Further key findings from the report suggest
• To capture significant clientele, companies are
  engaged in developing advanced automated products
  with enhanced efficiency and ease of use. For
  instance, in June 2020, Medtronic received the
  CE-Mark for its MiniMed 780G. The device
  automatically adjust basal insulin rates after
  every five minutes and is suitable for diabetic
  of 7- 80 year old
• Expansion of application range of products to
  address larger set of customers is another
  strategic initiative to enhance the business
  target which is likely to promote sales of AID
  products. For instance, in October 2019, Novo
  Nordisk received the U.S. Food and Drug
  Administration (FDA) approval for the expanded
  application of its Fiasp as insulin infusion
  pumps in adults with type 1 or type 2 diabetes as
  an improvement of glycemic control
• Rising diabetic population globally, many
  companies are investing to develop advanced
  technology. For instance, in February 2020,
  Becton, Dickinson and Company completed a
  clinical trial of its BD Libertas a wearable
  injectors
• Emerging technologies in medical device sector
  has been playing great role in rising the growth
  of AID. For instance, in March 2019, Abbott
  Laboratoriesand Novo Nordisk entered into
  non-exclusive partnership that will incorporate
  insulin dose data from Novo Nordisk pre-filled
  and durable connected pens directly into the
  digital health tools compatible with the
  FreeStyle Libre system
• Read More _at_ https//www.reportsanddata.com/report-
  detail/automated-insulin-delivery-systems-market

7
Our Approach
About Us

• Reports and Data is a market research and
  consulting company that provides syndicated
  research reports, customized research reports,
  and consulting services. Our solutions purely
  focus on your purpose to locate, target and
  analyze consumer behavior shifts across
  demographics, across industries and help clients
  make a smarter business decision. We offer market
  intelligence studies ensuring relevant and
  fact-based research across a multiple industries
  including Healthcare, Technology, Chemicals,
  Power, and Energy. We consistently update our
  research offerings to ensure our clients are
  aware about the latest trends existent in the
  market. Reports and Data has a strong base of
  experienced analysts from varied areas of
  expertise.
• Contact Us
• John Watson
• Head of Business Development
• Reports And Data Web www.reportsanddata.com
• Direct Line 1-212-710-1370
• E-mail sales_at_reportsanddata.com